Report: Coagulation Factors 2009: Target Pipeline and Competitor Benchmark Analysis TOC

1. Executive Summary

2. Overview: What you will find in the report and where

3. Introduction:

3.1 Commercial uses of coagulation factors
3.2 Epidemiology of coagulation disorders
3.3 Market size
3.4 Patent expiration
3.5 Industrial stakeholders

4. Target Pipeline Analysis

4.1 Factor VIII
4.2 Factor IX
4.3 Factor VII
4.4 von Willebrand Factor (vWF)
4.5 Other Coagulation Factors
4.6 Topical Coagulation Factors
4.7 Other Experimental Hemophilia Therapies

5. Corporate Benchmark Analysis

5.1 The TOP League
- 5.1.1 Baxter
- 5.1.2 Novo Nordisk
- 5.1.3 Bayer Schering Pharma
- 5.1.4 Wyeth
- 5.1.5 A Cross-Comparison
5.2 The Diversifying Companies
- 5.2.1 CSL
- 5.2.2 Octapharma
- 5.2.3 LFB
5.3 The Emerging Companies
- 5.3.1 Zymogenetics
- 5.3.2 Biogen Idec
- 5.3.3 Biovitrum
- 5.3.4 Inspiration Biopharmaceuticals
- 5.3.5 Ipsen
- 5.3.6 Green Cross
- 5.3.7 SK Chemicals
- 5.3.8 Thrombotargets
- 5.3.9 GTC Biotherapeutics
- 5.3.10 Pharming
- 5.3.11 ProFibrix
5.4 The Facilitator Companies
5.5 The Traditional Companies
5.6 The Unclassified Companies

6. References

7. Tables in the Text

Table 1 Prevalence of rare coagulation factor disorders
Table 2 2008 Sales of Recombinant Factor VIII Products
Table 3 Growth of the recombinant Factor VIII market (US$ mln)
Table 4 BeneFix Sales (1999 - 2008)
Table 5 NovoSeven Sales (1999 - 2008)
Table 6 Total Sales of recombinant coagulation factors in 2008
Table 7 2008 Sales of selected pd coag. factors for systemic use
Table 8 2008 Sales of selected pd coagulation factors for topical use
Table 9 2008 Sales of coagulation factor product lines per company
Table 10 Changes of manufacturing/formulation in rec. coag. factors
Table 11 Approval / launches of rec coag. factors in the US and EU
Table 12 The TOP coag. factor companies in terms of 2008 sales
Table 13 Product characteristics of improved rhu F. VIII products
Table 14 Overview of R&D pipeline of rec factor VIII products
Table 15 Target profiles of rec wild-type F. VIII products in R&D
Table 16 Target profiles of rec long-acting F. VIII products in R&D
Table 17 Product characteristics of marketed wt rhu F. IX
Table 18 Overview of R&D pipeline of rec factor IX products
Table 19 Target profiles of rec wild-type F. IX products in R&D
Table 20 Target profiles of rec long-acting F. IX products in R&D
Table 21 Product characteristics of marketed wt rhu F. VII
Table 22 Overview of R&D pipeline of rec factor VIIa products
Table 23 Target profile of rec wild-type F. VIIa product in R&D
Table 24 Target profiles of rec long-acting F. VIIa products in R&D
Table 25 Overview on Baxter' s R&D Pipeline in rec coag. factors
Table 26 SWOT analysis of Baxter
Table 27 Overview on Novo Nordisk' s R&D pipeline in coag. factors
Table 28 SWOT analysis of Novo Nordisk
Table 29 Overview on Bayer' s R&D pipeline in rec coag. factors
Table 30 SWOT analysis of Bayer Schering Pharma
Table 31 Overview on Wyeth' s R&D pipeline in rec coag. factors
Table 32 SWOT analysis of Wyeth
Table 33 Overview on TOP League' s R&D pipeline in r coag. factors
Table 34 The largest plasma fractionation companies by plasma vol.
Table 35 The largest plasma fractionation companies by sales
Table 36 SWOT analysis of CSL
Table 37 SWOT analysis of Octapharma
Table 38 SWOT analysis of LFB
Table 39 SWOT analysis of Zymogenetics
Table 40 SWOT analysis of Biogen Idec
Table 41 SWOT analysis of Biovitrum
Table 42 SWOT analysis of Inspiration Biopharmaceuticals
Table 43 SWOT analysis of Ipsen
Table 44 SWOT analysis of Green Cross
Table 45 Protein engineering companies (ref. rec coagulation factors)
Table 46 Drug delivery companies (ref. rec coagulation factors)
Table 47 Product portfolio of traditional plasma fract. companies
Table 48 R&D portfolio of traditional plasma fractionation companies

ADDENDUM

A) Executive Drug Profiles

40K PEG-rFIX
AV513
BAY 79-4980
BAY 86-6150
CSL689
FIXFc
GreenGene
IB1001
NN1731
NN1841
NN7008
NN7128
OBI-1
Octagenate
rVWF

B) Company Profiles

Amsterdam Molecular Therapeutics
Apitope
Asklepios Biopharmaceutical
Baxter
Bayer Schering Pharma
Bio Products Laboratory (BPL)
Biogen Idec
Biotest
Biovitrum
Catalyst Biosciences
Celestial Biologicals
China Biologic Products
Crucell
CSL
Ethicon (J&J)
Green Cross
Grifols
GTC Biotherapeutics
Haemacure
Inspiration Biopharmaceuticals
Intas Biopharmaceuticals
Ipsen
Jerini (Shire)
Kaketsuken
Kamada
Kedrion
King Pharmaceuticals
LFB
Lipoxen
Maxygen
MDRNA
MediVas
Mochida Pharmaceutical
National Bioproducts Institute (NBI)
Nautilus Biotech (HanAll Pharmaceutical)
Nektar Therapeutics
Neose Technologies
Novo Nordisk
Nycomed
Octapharma
Oxford Biomedica
Pharming
ProFibrix
ProGenetics
PROLOR Biotech
Recoly
Sanquin
Shanghai RAAS
SK Chemicals
Talecris Biotherapeutics
Thrombotargets
VIRxSYS
Wyeth
Zymogenetics

C) Tabulated Overviews on Profiles of Plasma Derived Coagulation Factors

Tab I: Profile of Human Plasma-Derived Coagulation Factor VIII Concentrates
Tab II: Profile of Highly Purified Human Plasma-Derived Coagulation Factor IX Concentrates
Tab III: Profile of Purified Human Plasma-Derived Prothrombin Complex Concentrates
Tab IV: Profile of Other Human Plasma-Derived Coagulation Factor Concentrates
Tab V: Profile of Topical Coagulation Factor Products & Projects

D) Tabulated Target Pipelines of Coagulation Factors

Tab VI: Human Plasma-Derived Coagulation Factor VIII Concentrates
Tab VII: Recombinant Coagulation Factor VIII Products
Tab VIII: Human Plasma-Derived Coagulation Factor IX Products
Tab IX: Recombinant Coagulation Factor IX Products
Tab X: Human Plasma-Derived Factor VII
Tab XI: Recombinant Coagulation Factor VII Products
Tab XII: Human Plasma-Derived Coagulation Factor Concentrates for vWD
Tab XIII: Recombinant Human Von Willebrand Factor Products
Tab XIV: Human Plasma-Derived Fibrinogen (Factor I)
Tab XV: Recombinant Human Fibrinogen Products
Tab XVI: Human Plasma-Derived Factor V
Tab XVII Human Plasma-Derived Factor XI
Tab XVIII: Human Plasma-Derived Factor X
Tab XIX: Recombinant Human Factor X
Tab XX: Human Plasma-Derived Factor XIII
Tab XXI: Recombinant Human Factor XIII
Tab XXII: Other Recombinant Factors
Tab XXIII: Other Experimental Hemophilia Therapies
Tab XXIV: Gene Therapy
Tab XXV: Topical Human Plasma-Derived Fibrinogen and Thrombin Products
Tab XXVI: Topical Plasma-Derived Thrombin Products
Tab XXVII: Human Plasma-Derived Prothrombin Complex Concentrates

E) Tabulated Corporate Product Portfolios and R&D Pipelines

Abraxis Biosciences
Amsterdam Molecular Therapeutics
Angiotech
Apitope
Asklepios Biopharmaceutical
Baxter
Bayer Schering Pharma
Bio Products Laboratory (BPL)
Biogen Idec
Biotest
Biovitrum
Catalyst Biosciences
China Biologic Products
Crucell
CSL
Ethicon (J&J)
Genzyme
Green Cross
Grifols
GTC Biotherapeutics
Haemacure
Inspiration Biopharmaceuticals
Intas Biopharmaceuticals
Ipsen
Jerini (Shire)
Kaketsuken
Kamada
Kedrion
King Pharmaceuticals
LFB
Lipoxen
Maxygen
MDRNA
MediVas
Mochida Pharmaceutical
National Bioproducts Institute (NBI)
Nautilus Biotech (HanAll Pharmaceutical)
Nektar Therapeutics
Neose Technologies
Novo Nordisk
Nycomed
Octapharma
Oxford Biomedica
Pharming
ProFibrix
ProGenetics
PROLOR Biotech
Recoly
Roche
Sanquin
Shanghai RAAS
Sinobiomed
SK Chemicals
Talecris Biotherapeutics
Thrombotargets
VIRxSYS
Wyeth

Zymogenetics

Coagulation Factors 2009: Target Pipeline and Competitor Benchmark Analysis

Table of Contents

1. Executive Summary

2. Overview: What you will find in the report and where

3. Introduction:

4. Target Pipeline Analysis

5. Corporate Benchmark Analysis

6. References

7. Tables in the Text

ADDENDUM

A) Executive Drug Profiles

B) Company Profiles

C) Tabulated Overviews on Profiles of Plasma Derived Coagulation Factors

D) Tabulated Target Pipelines of Coagulation Factors

E) Tabulated Corporate Product Portfolios and R&D Pipelines